Sign Out
Monotherapy: Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
Combination with metformin or PPARγ agonist: Sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin or a PPARγ agonist (i.e. thiazolidinediones) when the single agent alone, with diet and exercise, does not provide adequate glycemic control.
Combination with metformin and sulfonylurea: Sitagliptin is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin and a sulfonylurea when dual therapy with these agents, with diet and exercise does not provide adequate glycemic control.
Combination with insulin: Sitagliptin is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycemic control.
